Waverton Investment Management Ltd bought a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 101,906 shares of the life sciences company’s stock, valued at approximately $31,661,000. Illumina accounts for 1.7% of Waverton Investment Management Ltd’s holdings, making the stock its 20th largest holding. Waverton Investment Management Ltd owned about 0.07% of Illumina at the end of the most recent reporting period.
Several other large investors have also made changes to their positions in ILMN. Massmutual Trust Co. FSB ADV boosted its holdings in shares of Illumina by 83.0% in the fourth quarter. Massmutual Trust Co. FSB ADV now owns 86 shares of the life sciences company’s stock valued at $26,000 after purchasing an additional 39 shares during the period. Financial Advocates Investment Management raised its stake in Illumina by 1,430.0% in the fourth quarter. Financial Advocates Investment Management now owns 612 shares of the life sciences company’s stock worth $28,000 after buying an additional 572 shares in the last quarter. Proficio Capital Partners LLC raised its stake in Illumina by 61.7% in the fourth quarter. Proficio Capital Partners LLC now owns 97 shares of the life sciences company’s stock worth $29,000 after buying an additional 37 shares in the last quarter. Lake Point Wealth Management bought a new position in Illumina in the fourth quarter worth approximately $30,000. Finally, Moody National Bank Trust Division bought a new position in Illumina in the fourth quarter worth approximately $31,000. Institutional investors and hedge funds own 90.46% of the company’s stock.
Shares of ILMN stock traded down $4.78 during trading hours on Thursday, reaching $313.91. 12,679 shares of the company’s stock were exchanged, compared to its average volume of 961,204. The company has a market cap of $46.62 billion, a PE ratio of 55.27, a PEG ratio of 2.39 and a beta of 1.17. The company has a current ratio of 2.49, a quick ratio of 2.27 and a debt-to-equity ratio of 0.23. Illumina, Inc. has a fifty-two week low of $226.62 and a fifty-two week high of $372.61.
In related news, SVP Aimee L. Hoyt sold 298 shares of the company’s stock in a transaction on Tuesday, February 26th. The stock was sold at an average price of $304.63, for a total value of $90,779.74. Following the transaction, the senior vice president now directly owns 2,297 shares of the company’s stock, valued at approximately $699,735.11. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Jay T. Flatley sold 3,300 shares of the company’s stock in a transaction on Wednesday, April 10th. The shares were sold at an average price of $317.01, for a total value of $1,046,133.00. Following the completion of the transaction, the director now directly owns 331,668 shares in the company, valued at $105,142,072.68. The disclosure for this sale can be found here. Over the last three months, insiders sold 34,826 shares of company stock worth $10,604,560. 0.54% of the stock is owned by insiders.
ILMN has been the subject of a number of recent research reports. Zacks Investment Research raised shares of Illumina from a “hold” rating to a “buy” rating and set a $339.00 price objective for the company in a research note on Friday, February 22nd. Bank of America reissued a “buy” rating and issued a $355.00 price objective on shares of Illumina in a research note on Wednesday, January 30th. UBS Group raised shares of Illumina from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $340.00 to $370.00 in a research note on Thursday, January 3rd. BidaskClub raised shares of Illumina from a “hold” rating to a “buy” rating in a research note on Tuesday. Finally, Morgan Stanley reduced their price objective on shares of Illumina from $320.00 to $288.00 and set an “equal weight” rating for the company in a research note on Monday, January 7th. Three investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $346.97.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Further Reading: How liquidity affects the bid-ask spread
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.